5. ÚPLNÁ STRUKTUROVANÁ BIBLIOGRAFIE RNDr. Pavel Souček, CSc. 1) Monografie, kapitoly v monografiích, učebnice, překlady monografií a učebnic, učební texty 1. Souček P. Xenobiotics, In: Encyclopedia of Cancer, Schwab, M (Ed.), 2nd ed., 2008, Springer Verlag, 3235 pages. 2. Souček P. Význam genetických polymorfismů enzymů metabolizujících léčiva u nádorových onemocnění. In: Metabolismus léčiv a jiných xenobiotik (Ed. Skálová L. a kolektiv), vydalo Karolinum v Praze 2010, s.116-122, Monography in Czech. 3. Mohelnikova-Duchonova B, Soucek P. The Role of Membrane Transporters in Cellular Resistance of Pancreatic Carcinoma to Gemcitabine and Erlotinib. In: Horizons in Cancer Research, Volume 46, Watanabe H.S. (Ed.), 2012, NOVA Science Publishers Inc., NY, USA. 4. Souček P. Použití tkáňových modelů ve farmakogenetice nádorových onemocnění, In: Experimentální chirurgie - nové technologie v medicíně. I. díl: Experimentální chirurgie (Ed. Liška V., Rosenberg J. a kol.) vydala Univerzita Karlova v Praze, Lékařská fakulta v Plzni, 2013 s. 96-118, Monography in Czech. 2) Původní vědecké práce v mezinárodních časopisech s recenzním řízením 1. Gut I, Terelius Y, Frantik E, Linhart I, Souček P, Filipcova B and Klučkova H, (1993) Effect of Exposure to Benzene and its Derivatives on Hepatic Microsomal P450 Forms and on Benzene, Toluene, Chlorobenzene and Aniline Metabolism. Arch Toxicol. 67, 237-243. IF = 1.38 2. Souček P, Filipcova B and Gut I, (1994) Destruction of Cytochrome P450 by Benzene and its Metabolites in vitro. Evidence for the Key Role of Quinones. Biochem. Pharmacol. 47, 2233-2242. IF = 2.26 3. Souček P, Martin, M.V., Ueng YF, and Guengerich, (1995) Identification of a Common Cytochrome P450 Epitope Near the Conserved Heme-binding Peptide with Antibodies Raised Against Recombinant Cytochrome P450 Family 2 Proteins. Biochemistry 34, 16013-16021. IF = 5.14 4. Gut I, Nedelcheva V, Souček P, Stopka P, Vodička P, Gelboin HV, and Sundberg M-I, (1996) The Role of CYP2E1 and 2B1 in metabolic Activation of Benzene Derivatives. Arch. Toxicol. 71, pp. 45-56. IF = 1.11 5. Tateishi T, Soucek P, Caraco Z, Guengerich FP, and Wood AJJ (1997) Colchicine biotransformation by human liver microsomes. Biochem. Pharmacol. 53, 111-116. IF = 2.44 6. Anzenbacher P, Souček P, Gut I, Hrubý K, Anzenbacherová E, Svoboda Z, and Květina J, (1998) Presence and activity of cytochrome P-450 isoforms in minipig liver microsomes: comparison with human liver samples. Drug Metab. Dispos. 26, 56-59. IF = 2.27 7. Nedelcheva, V., Gut, I., Souček, P., and Frantík, E. (1998) Cytochrome P450 catalyzed oxidation of monochlorobenzene, 1,2- and 1,4-dichlorobenzene in rat, mouse and human liver microsomes. Chem-Biol. Interact. 115, 53-70. IF = 1.20 8. Nedelcheva V, Gut I, Souček P, Tichavská B, Týnková L, Mráz J, Guengerich FP and Ingelman-Sundberg M (1999) Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. Arch. Toxicol. 73, 33-40. IF = 1.68 9. Souček P (1999) Cytochrome P450 destruction by quinones. Comparison of effects in rat and human liver microsomes. Chem-Biol. Interact. 121, 223-236. IF = 1.89 10. Souček P (1999) Expression of cytochrome P450 2A6 in Escherichia coli, purification, spectral, and catalytic characterization, and preparation of polyclonal antibodies. Arch. Biochem. Biophys. 370, 190-200. IF = 2.39 1
11. Souček P (1999) Novel sensitive high performance liquid chromatographic method for assay of coumarin 7- hydroxylation. J Chromatogr B, 734, 23-29. IF = 1.67 12. Gillam EMJ, Aguinaldo A-M, Notley LM, Kim D, Mundowski RG, Volkov AA, Arnold FH, Souček P, DeVoss J, and Guengerich FP. (1999) Formation of indigo by recombinant mammalian cytochrome P450. Biochem. Biophys. Res. Commun. 265, 469-472. IF = 3.16 13. Souček P, Gut I, and Stopka P. (2000) Effect of the microsomal system of interconversions between hydroquinone, benzoquinone, oxygen activation, and lipid peroxidation. Chem-Biol. Interact. 126, 45-61. IF = 1.89 14. Anzenbacherová E, Bec N, Anzenbacher P, Hudeček J, Souček P, Jung C, Munro AW, and Lange R. (2000) Flexibility and stability of the structure of cytochrome P450 3A4 and BM-3 Eur. J. Biochem., 267, 2916-2920. IF = 2.85 15. Šarmanová J, Týnková L, Šůsová S, Gut I, and Souček P. (2000) Genetic polymorphisms of biotransformation enzymes: allele frequencies in the population of the Czech Republic. Pharmacogenetics, 10, 781-788. IF = 4.47 16. Bořek-Dohalská L, Gut I, Souček P, Roth and Hodek P. (2000) Cytochrome P450 enzymes involved in docetaxel, paclitaxel, and cyclophosphamide metabolism in rats. Collect. Czech Chem. Commun 65, 1183-1190. IF = 0.96 17. Gut I, Danielová V, Holubová J, Souček P, Klučková H. (2000) Cytotoxicity of cyclophosphamide, paclitaxel and docetaxel for tumor cells lines in vitro: effects of concentration, time, and cytochrome P450- catalyzed metabolism. Arch Toxicol. 74, 437-446. IF = 2.01 18. Souček P. (2001) Role of genetic factors in development and progression of non-hodgkin's lymphomas. Central European Journal of Public Health 9, 74-78. bez IF 19. Šarmanová J, Benešová K, Gut I, Nedelcheva Kristensen V, Týnková L, Souček P. (2001) Genetic Polymorphisms of Biotransformation Enzymes in Patients with Hodgkin s and non-hodgkin s Lymphomas Hum. Mol. Genet., 10, 1265-1273. IF = 9.32 20. Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, Vodickova L, Koskinen M, de Zwart MA, Natarajan AT and Hemminki K. (2001) Association between genetic polymorphism and biomarkers in styrene-exposed workers. Mutat. Res. 482, 89-103. IF = 2.55 21. Soucek P, Zuber R, Anzenbacherova E, Anzenbacher P, and Guengerich FP. (2001) Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol, 1(1),11. bez IF 22. Skalova L, Szotakova B, Machala M, Neca JV, Soucek P, Havlasova J, Wsol V, Kridova L, Kvasnickova E, Lamka JV, (2001) Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama). Chem-Biol Interact 137(2), 155-67. IF = 1.71 23. Anzenbacher P, Anzerbacherova E, Zuber R, Soucek P, and Guengerich FP. (2002) Pig and minipig cytochromes P450. Drug Metab Dispos, 30(1), 100-2. IF = 3.28 24. Soucek P, Gut I, Trněný M, Skovlund E, Kristensen T, Børresen-Dale A-L, and Kristensen VN. (2003) Multiplex single-tube screening for mutations in the nijmegen breakage syndrome (NBS1) gene in Hodgkin s and non-hodgkin s lymphoma patients of slavic origin. Eur. J. Hum. Genet. 11: 416-419. IF = 3.67 25. Vodicka P, Koskinen M, Stetina R, Soucek P, Vodickova L, Matousu Z, Kuricova M, Hemminki K. (2003) The role of various various biomarkers in the evaluation of styrene genotoxicity. Cancer Detect. Prev. 27:275-84. IF = 1.18 26. Machala M, Souček P, Neča J, Ulrich R, Lamka J, Szotáková B, Baliharová V, Skálová L. (2003) Interspecies comparisons of hepatic cytochrome P450 enzyme levels in male wild ruminants. Arch. Toxicol., 2
77:555-560. IF = 1.60 27. Szotáková B, Baliharová B, Lamka J, Nožinová E, Wsól V, Velík J, Machala M, Neča J, Souček P, Šůsová S and Skálová L. (2004) Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat, and sheep. Res. Vet. Sci., 76:43-51. IF = 1.15 28. Vodička P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, Dusinska M, Kuricova M, Zamecnikova M, Musak L, Buchancova J, Norppa H, Hirvonen A, Vodickova L, Naccarati A, Matousu Z and Hemminki K (2004). Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis, 25: 757-763. IF = 5.38 29. Menzel H-J, Sarmanova J, Soucek P, Berberich R, Grünewald K, Haun M, Kraft H-G. (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br. J. Cancer, 90: 1989-1994. IF = 3.74 30. Šarmanová J, Šůsová S, Gut I, Mrhalová M, Kodet R, Adámek J, Roth Z, and Souček P. (2004) Breast cancer: role of polymorphisms in biotransformation enzymes. Eur. J. Hum. Genet., 12(10):848-854. IF = 2.74 31. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, and Gut I. (2004) Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab. Dispos, 32: 666-674. IF = 3.84 32. Kubrycht J, Borecky J, Soucek P, Jezek P. (2004) Sequence similarities of protein kinase substrates and inhibitors with immunoglobulins and model immunoglobulin homologue: cell adhesion molecule from the living fossil sponge Geodia cydonium. Mapping of coherent database similarities and implications for evolution of CDR1 and hypermutation. Folia Microbiol (Praha),49(3):219-246. IF = 0.51 33. Vodicka P, Kumar R, Stetina R, Musak L, Soucek P, Haufroid V, Sasiadek M, Vodickova L, Naccarati A, Sedikova J, Sanyal S, Kuricova M, Brsiak V, Norppa H, Buchancova J and Hemminki K. (2004) Markers of individual susceptibility and dna repair rate in workers exposed to xenobiotics in a tire plant. Environ. Molec. Mutagen., 44(4):283-292. IF = 2.00 34. Soucek P, Skjelbred CF, Svendsen M, Kristensen T, Kure EH, Kristensen VN. (2004) Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) gene. BMC Biotechnol. 254(1):28. bez IF 35. Souček P, Anzenbacher P, Skoumalová I, and Dvořák M (2005) Expression of Cytochrome P450 Genes in CD34 + Hematopoietic Stem and Progenitor Cells. Stem Cells, 23: 1417-1422. IF = 6.09 36. Baranová J, Anzenbacherová E, Anzenbacher P, and Souček P (2005) Minipig Cytochrome P450 2E1: Comparison with Human Enzyme. Drug Metab. Dispos, 33(6):862-865. IF = 4.02 37. Naccarati A, Soucek P, Stetina R, Haufroid V, Kumar R, Vodickova L, Trtkova K, Dusinska M, Hemminki K, and Vodicka P. (2006) Genetic polymorphisms and possible gene-gene interactions in metabolic and dna repair genes: effects on DNA damage. Mutat. Res.- Fund. Mol. M, 593(1-2) :22-31. IF = 4.11 38. Šůsová S, Trněný M, and Souček P (2006) Single nucleotide polymorphism in 5 -flanking region of BCL6 is not associated with increased risk of non-hodgkin s lymphoma. Cancer Lett., 238: 142-145. IF = 3.28 39. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295(12):1379-88. IF = 23.17 40. Stiborová M, Dračínská H, Hájková J, Kadeřábková P, Frei E, Schmeiser HH, Souček P, Phillips DH, and Arlt VM (2006) The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and -1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab Dispos, 34: 1398-1405. IF = 3.64 41. Otova B, Vaclavikova R, Ehrlichova M, Horsky S, Soucek P, Simek P, Gut I. (2006) Effects of paclitaxel, 3
docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats. Eur J Pharm Sci, 29(5):442-450. IF = 2.48 42. Gut I, Ojima I, Vaclavikova R, Simek P, Horsky S, Linhart I, Soucek P, Kondrova E, Kuznetsova LV, Chen J. (2006) Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica, 36(9):772-92. IF = 1.61 43. Vodicka P, Stetina R, Polakova V, Tulupova E, Naccarati A, Vodickova L, Kumar R, Hanova M, Pardini B, Slyskova J, Musak L, De Palma G, Soucek P, Hemminki K. (2007) Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis, 28(3):657-664. IF = 5.41 44. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, Li D, Parl FF, Rylander- Rudqvist T, Soucek P, Zheng W, Wedren S, Taioli E. (2007) Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol. 165(2):115-25. IF = 5.29 45. Soucek P, Borovanova T, Pohlreich P, Kleibl Z, Novotny J. (2007) Role of Single Nucleotide Polymorphisms and Haplotypes in BRCA1 in Breast Cancer: Czech Case-Control Study. Breast Cancer Res Treat.103(2):219-224. IF = 4.45 46. Kondrová E, Stopka P, Souček P (2007) Cytochrome P450 destruction by metabolites of benzene and the formation of hydroxyl radicals in minipig liver microsomes. Toxicol in vitro, 21(4):566-575. IF = 2.19 47. Slyskova J, Dusinska M, Kuricova M, Soucek P, Vodickova L, Susova S, Naccarati A, Tulupova E, Vodicka P. (2007) Relationship between the capacity to repair 8-oxoguanine, biomarkers of genotoxicity and individual susceptibility in styrene-exposed workers. workers. Mutat Res-Gen Tox Environm Mutag, 634 (1-2): 101-111. IF = 2.28 48. Vaclavikova R, Hubackova M, Stribrna-Sarmanova, J, Kodet R, Mrhalova M, Novotny J and Soucek P. (2007) RNA expression of cytochromes P450 in breast cancer patients. Anticancer Res. 27(6C):4443-50. IF = 1.41 49. Vaclavikova, Kondrova E, Ehrlichova M, Boumendjel A, Kovar J, Stopka P, Soucek P and Gut I (2008) The effect of flavonoid derivatives on doxorubicin transport and metabolism, Bioorg Med Chem, 16(4):2034-42. IF = 3.08 50. Vaclavikova R, Nordgard SH, Alnaes GIG, Hubackova M, Kubala E, Kodet R, Mrhalova M, Novotny J, Gut I, Kristensen VN and Soucek P (2008) Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients, Pharmacogenet Genomics 18(3):263-273. IF = 4.41 51. Musak L, Soucek P, Vodickova L, Naccarati A, Halasova E, Polakova V, Slyskova J, Susova S, Buchancova J, Smerhovsky Z, Sedikova J, Klimentova G, Osina O, Hemminki K, Vodicka P. (2008) Chromosomal aberrations in tire plant workers and interaction with polymorphisms of biotransformation and DNA repair genes. Mutat Res- Fund Mol M, 10;641(1-2):36-42. IF = 3.20 52. Kleibl Z, Havranek O, Novotny J, Kleiblova P, Soucek P, Pohlreich P. (2008) Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations Breast Cancer Res Treat;112(1):159-64. IF = 5.68 53. Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, Soucek P. (2009) The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer, 45(4):618-24. IF = 4.12 54. Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I and Soucek P. (2009) NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not co-segregate with clinico-pathological characteristcs of human mammary tumors. Pharmacogenet Genomics 19(7):505-512. IF = 3.99 4
55. Pardini B, Naccarati A, Polakova V, Smerhovsky Z, Hlavata I, Soucek P, Novotny J, Vodickova L, Tomanova V, Landi S, Vodicka P (2009) NBN 657del(5) heterozygous mutations and colorectal cancer risk in the Czech Republic. Mutat Res- Fund Mol M 666(1-2):64-7. IF = 3.56 56. Ueng YF, Chen CC, Tsai CC, Soucek P. (2009) Differential inductive profiles of hepatic cytochrome P450s by the extracts of Sophora flavescens in male and female C57BL/6JNarl mice. J Ethnopharmacol 10;126(3):437-46. IF = 2.32 57. Vodicka P, Naccarati A, Vodickova L, Polakova V, Dusinska M, Musak L, Halasova E, Susova S, Soucek P, Hemminki K. (2009) Do GST polymorphisms modulate the frequency of chromosomal aberrations in healthy subjects? Environ Health Perspect 117(9):A384-5. IF = 6.19 58. Vrana D, Pikhart H, Mohelnikova-Duchonova B, Holcatova I, Strnad R, Slamova A, Schejbalova M, Ryska M, Susova S, Soucek P. (2009) The association between Glutathione S-transferase Gene polymorphisms and pancreatic cancer in Central European Slavonic population. Mutat Res-Gen Tox Environm Mutag 680:78 81. IF = 2.55 59. Vrana D, Novotny J, Holcatova I, Hlavata I, Soucek P. (2010) CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival. Neoplasma 57(1):15-9. IF = 1.449 60. Mohelnikova-Duchonova B, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Soucek P. (2010) CYP2A13, ADH1B and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk. Pancreas, 39(2):144-148. IF = 2.607 61. Chou YC, Chung YT, Liu TY, Wang SY, Chau GY, Chi CW, Soucek P, Krausz KW, Gelboin HV, Lee CH, Ueng YF. (2010) The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J Pharmacol Sci, 99(2):1063-77. IF = 2.260 62. Naccarati A, Pardini B, Polakova V, Smerhovsky Z, Vodickova L, Soucek P, Vrana D, Holcatova I, Ryska M, Vodicka P. (2010) Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. Carcinogenesis 31(4):666-70. IF = 5.402 63. Mateju M, Stribrna J, Zikan M, Kleibl Z, Janatova M, Kormunda S, Novotny J, Soucek P, Petruzelka L, Pohlreich P. (2010) Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers. Neoplasma 57(3):280-5. IF = 1.449 64. Méplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, Hlavatá I, Vrána D, Vodicka P, Hesketh JE. (2010) Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 31(6):1074-9. IF = 5.402 65. Soucek P, Susova S, Mohelnikova-Duchonova B, Gromadzinska J, Morawiec-Sztandera A, Vodicka P, Vodickova L (2010) Polymorphisms in xenobiotic-metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. Neoplasma 57(5):415-21. IF = 1.449 66. Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati B, Vodicka P, Novotny J, Mohelnikova- Duchonova B, Soucek P. (2010) Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1, and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep, 24(5):1347-53. IF = 1.686 67. Mohelnikova-Duchonova B, Havranek O, Hlavata I, Foretova L, Kleibl Z, Pohlreich P, Soucek P. (2010) CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer. Cancer Epidemiology, 34(5):656-658. IF = 1.182 68. Hanova M, Stetina R, Vodickova L, Vaclavikova R, Hlavac P, Smerhovsky Z, Naccarati A, Polakova V, Soucek P, Kuricova M, Manini P, Kumar R, Hemminki K, Vodicka P. (2010) Modulation of DNA repair capacity and mrna expression levels of XRCC1, hogg1 and XPC genes in styrene-exposed workers. Toxicol Appl Pharmacol, 248(3):194-200. IF = 3.993 69. Hanova M, Vodickova L, Vaclavikova R, Smerhovsky Z, Stetina R, Hlavac P, Naccarati A, Slyskova J, 5
Polakova V, Soucek P, Kumar R, Hemminki K, Vodicka P. DNA damage, DNA repair rates and mrna expression levels of cell cycle genes (TP53, p21cdkn1a, BCL2 and BAX) with respect to occupational exposure to styrene. Carcinogenesis 2011;32(1):74-9. IF = 5.702 70. Mohelnikova-Duchonova B, Marsakova L, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Slamova A, Schejbalova M, Soucek P. Superoxide Dismutase and NAD(P)H Quinone Oxidoreductase Polymorphisms and Pancreatic Cancer Risk. Pancreas 2011;40(1):72-78. IF = 2.386 71. Soucek P, Kondrova E, Hermanek J, Stopka P, Boumendjel A, Ueng YF, Gut I. (2011) New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anti-cancer Drugs, 22(2):176-84. IF = 2.407 72. Hughes DJ, Hlavatá I, Soucek P, Pardini B, Naccarati A, Vodickova L, Jenab M, O Morain C, and Vodicka P. (2011) Variation in the Vitamin D receptor gene is not associated with Colorectal Cancer in the Czech Republic. Journal of Gastrointestinal Cancer, 42(3):149-54. bez IF 73. Hughes D, Hlavatá I, Soucek P, Pardini B, Naccarati A, Vodickova L, O'Morain C, Vodicka P. (2011) Ornithine Decarboxylase G316A Genotype and Colorectal Cancer Risk. Colorectal Dis, 13(8):860-4. IF = 2.927 74. Ueng YF, Chen CC, Chung YT, Liu TY, Chang YP, Lo WS, Murayama N, Yamazaki H, Souček P, Chau GY, Chi CW, Chen RM, Li DT. (2011) Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol, 163(6):1250-62. IF = 4.409 75. Havranek O, Spacek M, Hubacek P, Mocikova H, Benesova K, Soucek P, Trneny M, Kleibl Z. (2011) No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-hodgkin lymphoma. Leukemia Res, 35(8):1117-9. IF = 2.923 76. Hubackova M, Vaclavikova R, Ehrlichova M, Mrhalova, Kodet R, Kubackova K, Vrána D, Gut I, Soucek P. (2012) Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer, 130(2):338-48. IF 2011 = 5.444 77. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka, P, Soucek P. (2012) The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis, 27(2):187-96. IF 2011 = 3.183 78. Mohelnikova-Duchonova B, Oliverius M, Honsova E, Soucek P. (2012) Evaluation of reference genes and normalization strategy for quantitative real-time PCR in human pancreatic carcinoma. Dis Markers, 32(3):203-10. IF 2011 = 1.642 79. Otová B, Ojima I, Václavíková R, Hrdý J, Ehrlichová M, Souček P, Vobořilová J, Němcová V, Zanardi I, Horský S, Kovář J, Gut I. (2012) Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Invest New Drugs; 30:991 1002. IF 2011 = 3.357 80. Ehrlichová M, Ojima I, Chen J, Václavíková R, Němcová-Fürstová V, Vobořilová J, Simek P, Horský S, Souček P, Kovář J, Brabec M, Gut I. (2012) Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells. Naunyn Schmiedebergs Arch Pharmacol,.385(10):1035-48. IF 2011 = 2.647 81. Vaclavikova R, Ehrlichova M, Hlavata I, Pecha V, Kozevnikovova R, Trnkova M, Adámek J, Edvardsen H, Kristensen VN, Gut I and Soucek P. (2012) Detection of frequent ABCB1 polymorphisms by highresolution melting curve analysis and their effect on breast carcinoma prognosis. Clin Chem Lab Med, 50(11):1999 2007. IF 2011 = 2.150 82. Lo WS, Lim YP, Chen CC, Hsu CC, Souček P, Yun CH, Xie W, Ueng YF. (2012) A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation. Arch Toxicol, 86(12):1927-38. IF 2011 = 4.674 6
83. Slyskova J, Korenkova V, Collins AR, Prochazka P, Vodickova L, Svec J, Lipska L, Levy M, Schneiderova M, Liska V, Holubec L, Kumar R, Soucek P, Naccarati A, Vodicka P. (2012) Functional, genetic and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. Clin Cancer Res, 18(21):5878-5887. IF 2011 = 7.742 84. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova E, Kala Z, Muckova K, Soucek P. (2012) Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas in press. IF 2011 = 2.386 85. Campa D, Rizzato C, Capurso G, Giese N, Funel N, Greenhalf W, Soucek P, Gazouli M, Pezzilli R, Pasquali C, Talar-Wojnarowska R, Cantore M, Andriulli A, Scarpa A, Jamroziak K, Fave GD, Costello E, Khaw KT, Heller A, Key TJ, Theodoropoulos G, Malecka-Panas E, Mambrini A, Bambi F, Landi S, Pedrazzoli S, Bassi C, Pacetti P, Piepoli A, Tavano F, di Sebastiano P, Vodickova L, Basso D, Plebani M, Fogar P, Büchler MW, Bugert P, Vodicka P, Boggi U, Neoptolemos JP, Werner J, Canzian F. (2012) Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis. 2012 Nov 30. doi:pii: S1590-8658(12)00372-6. [Epub ahead of print] IF 2011 = 3.054 86. Campa D, Rizzato C, Bauer AS, Werner J, Capurso G, Costello E, Talar-Wojnarowska R, Jamroziak K, Pezzilli R, Gazouli M, Khaw KT, Key TJ, Bambi F, Mohelnikova-Duchonova B, Heller A, Landi S, Vodickova L, Theodoropoulos G, Bugert P, Vodicka P, Hoheisel J, Delle Fave G, Neoptolemos J, Soucek P, Buchler MW, Giese NA, Canzian F. (2012) Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Cancer Epidemiol Biomarkers Prev. 2012 Dec 18. [Epub ahead of print]. IF 2011 = 4.123 87. Brynychová V, Hlaváč V, Ehrlichová M, Václavíková R, Pecha V, Trnková M, Wald M, Mrhalová M, Kubáčková K, Pikus T, Kodet R, Kovář J, Souček P. (2012) Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. Future Oncology accepted IF 2011 = 3.163 3) Vědecké práce v národních časopisech s recenzním řízením 1. Gut I, Milfajtová J, Patzelová V, Frantík E, Šarmanová J, Souček P, Vodička P. (2001) Úloha polymorfismu genotypu a fenotypu P450 2E1 a P450 2D6 v metabolismu a účincích léčiv a karcinogenů. Klin Onkol, 14: 193 196. 2. Souček P, Šarmanová J, Šůsová S, Týnková L, Benešová K, Vodička P a Gut I (2002) Genetické polymorfismy biotransformačních enzymů a jejich sledování v populaci České Republiky. Klin. Onkol, 15(5): 161-165. 3. Šůsová S, Novotný J, Vodička P a Souček P. (2005) Úloha genetických polymorfismů biotransformačních enzymů v rozvoji kolorektálního karcinomu. Klin. Onkol, 18: 188-193. 4. Kubala E, Kubáčková K, Horský S, Václavíková R, Souček P, Mrhalová M, Kodet R, Roth Z, Tomášek L, Gut I. (2007) Individuální rozdíly farmakokinetiky taxolu u pacientek s rakovinou prsu. Klin Farmakol Farm, 21:7 11. 5. Václavíková R., Hubáčková M., Kubala E., Kodet R., Mrhalová M., Novotný J., Gut I., Souček P., (2007) Exprese genu mnohočetné lékové rezistence 1 (MDR1) a její význam v rozvoji a terapii karcinomu prsu. Klin Onkol, 20: 253-259. 6. Hubáčková M., Václavíková R., Kubala E., Kodet R., Mrhalová M., Novotný J., Vrána D., Gut I. a Souček P. (2007) Úloha exprese genů chinonoxidoreduktázy 1 a 2 v rozvoji karcinomu prsu. Klin Onkol, 20:337-341. 7. Holcátová I, Souček P, Vrána D, Slámová A, Schejbalová M, Ryska M, Brabec M. (2009) Nádory slinivky břišní II. Potenciální rizikové faktory. Praktický lékař 8: 462. 4) Učebnice a učební texty 7
5) Vědecké práce ve sbornících včetně sborníků z konferencí s plným otištěným textem a/ vydávané v zahraničí 1. Souček P, Guo Z, Sandhu P, Martin MV, Cosme J, Beaune PH and Guengerich FP. (1996) Identification of Highly Polymorphic S-Mephenytoin Hydroxylase in Humans, Arch. Toxicol, Suppl 18: 435-437. IF = 1.11 2. Gut I, Nedelcheva V, Souček P, Stopka P, and Tichavska B, (1996) Cytochromes P450 in Benzene Metabolism and Involvement of Their Metabolites and Reactive Oxygen Species in Toxicity, Environ. Health Perspect, 104, Suppl. 6: 1211-1218. IF = 1.69 3. Vodička P, Bastlová T, Osterman-Golkar S, Vodičková L, Peterková K, Souček P, Šarmanová J, Farmer PB, Lambert B, and Hemminki K. (1999) An evaluation of styrene genotoxicity using several biomarkers in a three-year follow up study of hand lamination workers. Mutat. Res, 445: 205-24. IF = 2.11 4. Somorovska M, Jahnova E, Tulinska J, Zamecnikova M, Sarmanova J, Terenova A, Vodickova L, Liskova A Vallova B, Soucek P, Hemminki K, Norppa H, Hirvonen A, Tates AD, Fuortes L, Dusinska M, Vodicka P (1999) Biomonitoring of occupational exposure to styrene in a plastics lamination plant. Mutat. Res, 428: 255-69. IF = 2.11 5. Soucek, P. and Gut, I. (2001) Effect of the microsomal system on quinone redox cycling, oxygen activation, and lipid peroxidation. Adv Exp Med Biol, 500: 351-4. IF = 0.45 6. Vodička P, Štětina R, Koskinen M, Souček P, Vodičková L, Hlaváč P, Kuricová M, Nečasová R, Hemminki K (2002). New aspects in biomonitoring occupational exposure to styrene. Int. Arch. Occ. Env. Health, 75: S75-S85. IF = 1.35 7. Souček P, Šarmanová, Nedelcheva Kristensen V, Apltauerová, M, and Gut I (2002) Genetic polymorphisms of biotransformation enzymes in patients with hodgkin s and non-hodgkin s lymphomas. Int. Arch. Occ. Env. Health, 75: S86-S92. IF = 1.35 8. Anzenbacherova E, Baranova J, Zuber R, Pechova A, Anzenbacher P, Soucek P, Martinkova J. (2005) Model Systems Based on Experimental Animals for Studies on Drug Metabolism in Man: (Mini)Pig Cytochromes P450 3A29 and 2E1. Basic Clin Pharmacol Toxicol, 96(3):244-245. bez IF 9. Musak L, Vodicka P, Klimentova G, Soucek P, Hanova M, Mikulkova R, Buchancova J, Vodickova L, Polakova V, Pec M. (2006) Chromosomal damage and polymorphisms of DNA repair genes XRCC1 and XRCC3 in workers exposed to cytostatics. Neuroendocrinol Lett, 27(Suppl2):57-60. IF = 0.92 b/ vydávané v ČR 1. Gut I and Souček P. (1993) Covalent Binding of Benzene and its Metabolites to Biomacromolecules in Vitro. Plzeň. Lék. Sborn., Suppl. 67: 89-94. bez IF 6) Referátové a přehledové články (zahraniční, národní) 1. Souček P and Gut I. (1992) Rat Liver Cytochrome P450 Forms: Structure, Function, Properties and Relevant Human Forms. Xenobiotica 22: 83-103. IF = 1.04 2. Souček P and Gut I. (1993) Co je to cytochrom P450? Čas. Lék. Českych. 132: 353-358 (in Czech). 3. Gut I, Souček, P, and Hodek P. (1993) Monooxygenasy závislé na cytochromu P450. Pracov. Lék. 45: 15-20 (in Czech). 4. Šarmanová J, Týnková L, Gut I a Souček P. (2001) Genotypování biotransformačních enzymů Remedia 11: 3-13 (in Czech). 8
5. Borovanová T a Souček P. (2002) Rakovina prsu: přehled faktorů ovlivňujících vznik a rozvoj onemocnění. Čas. Lék. Českých, 141(3):80-84 (in Czech). 6. Kubrycht J, Sigler K, Ruzicka M, Soucek P, Borecky J, Jezek P. (2006) Ancient Phylogenetic Beginnings of Immunoglobulin Hypermutation. J Mol Evol, 63(5):691-706. IF = 2.77 7. Mohelníková-Duchoňová B, Souček P. (2010) Role membránových transportérů v chemorezistenci karcinomu pankreatu při terapii gemcitabinem. Klin Onkol, 23:306-310 (in Czech). 8. Kubrycht J, Sigler K, Souček P. (2012) Virtual interactomics of proteins from biochemical standpoint. Mol Biol Int, 2012:976385. bez IF 7) Přednášky typu invited speakers 1. Souček, P: Studium prognostických a prediktivních faktorů u karcinomu prsu. Vyžádaná přednáška na semináři Ústavu biologie a lékařské genetiky, 2LF UK, 24. listopad 2009, Praha, ČR. 2. Soucek P: Breast Cancer Prognosis and Therapy Outcome - The Role of ABC Transporters. Vyžádaná přednáška na National Research Institute of Chinese Medicine, 26. květen 2010, Taipei, Taiwan R.O.C. 3. Souček P: Genetic factors and prognosis of breast cancer therapy. Vyžádaná přednáška na Národní informační den k 6. výzvě priority Health 7. rámcového programu EU (7. RP), 15. červen 2011, Praha, ČR. 4. Soucek P., Hlavac V., Hlavata I., Pecha V., Trnkova M., Liska V., Vaclavikova R.: Role of ABC transporters in clinical outcome of cancer. Vyžádaná přednáška na konferenci 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine, 6-8. říjen 2011, Rhodos, Řecko. 5. Václavíková R, Hlaváč V, Mohelníková-Duchoňová B, Hlavatá I, Pecha V, Trnková M, Liška V, Oliverius M, Honsová E, Souček P. Role of ABC transporters in response of solid tumors to treatment. Vyžádaná přednáška na Pracovný deň liekovej rezistencie, 9. listopad 2011, Bratislava, Slovenská republika. 6. Souček P.: Genetické markery prognózy a predikce nádorových onemocnění. Seminář v rámci kurzu Pokroky v genetice, 18 duben 2012, Biologické centrum AV ČR, České Budějovice, ČR. 7. Souček P.: Pharmacogenomics in colorectal and breast cancers. 8 th Golden Helix Pharmacogenomics Day, 30. listopad 2012, Czech Ombudsman s Office Meeting Hall, Brno, ČR. 8. Soucek P, Vaclavikova R, Mohelnikova-Duchonova B, Hlavac V, Brynychova V, Hlavata I, Pecha V, Trnkova M, Liska V, Oliverius M, Kala Z, Gut I. Drug metabolizing enzymes and transporters as biomarkers of cancer therapy outcome. 17th World Congress on Advances in Oncology and 15th International Symposium on Molecular Medicine, 10-13 říjen 2012, Hersonissos, Řecko. 8) Patenty národní a zahraniční, objevy 9) Přednášky a postery na mezinárodních konferencích, sympoziích a odborných setkáních a/ postery 1. Gut I. Frantik E. Soucek P. Filipcova B: Metabolism of benzene-derivatives by P450IIB1 and P450IIE1 to protein-bound and DNA-bound products. Mutat Res 271 (2): 172-172, 1992, 6th IUTOX Conference, 29 June 3 July, 1992, Rome, Italy 2. Gut I. and Soucek P: Covalent binding of benzene and its metabolies to biomacromolecules in vitro. Investigation on the role of cytochrome P450 2B1 and P450 2E1. Proceedings of Molecular Aspects of Oxidative Drug Metabolizing Enzymes: NATO Advanced Study Institute Series, June 20 July 2, 9
1993, Kusadasi, Turkey 3. Soucek P. Guo Z. Sandhu P. Martin MV. Guengerich FP: Immunochemical cross-reactivity of human cytochrome-p450 enzymes analyzed with recombinant proteins. FASEB J 8 (7): A1248-A1248, 1994, ASBMB/ISSX Meeting, Cytochromes P450: Structure, Function, Regulation and Genetics, 21 25 May, 1994, Washington D.C., USA 4. Guengerich FP. Soucek P. Martin MV. Ueng YF. Bell LC: Identification of a common epitope near the conserved heme peptide in several cytochrome-p450 enzymes. FASEB J 9 (6): A1487-A1487, 1995, April 1995, ASBMB Meeting, San Francisco, USA 5. Souček P., Guo Z., Sandhu P., Martin M.V., Cosme J., Beaune P.H. and Guengerich F.P: Identification of highly polymorphic S-mephenytoin hydroxylase in humans. Toxicol Lett Suppl 1/78: 75, 1995, 34th EUROTOX Meeting, 27 30 August, 1995, Praha, Czech Republic 6. Anzenbacher P, Souček P, Gut I, Hrubý K, Anzenbacherová E, and Květina J: Cytochrome P-450 3A, the most important enzyme of drug metabolism in human liver, is present in minipig liver microsomes in similar content and activity to human samples. Proceedings of 6th European ISSX Meeting, 30 June 3 July, 1997, Goeteborg, Sweden 7. Souček P and Gut I: Cytochrome P450 destruction by benzene: comparison of effects in rat and human liver microsomes. FASEB J 11 (9): P191 Suppl. S, 1997, 17th International Congress of Biochemistry and Molecular Biology, 24 28 August, 1997, San Francisco, USA 8. Souček P and Gut I: Interconversions between hydroquinone, semiquinone, and benzoquinone: study of the involvement of microsomal system. Proceedings of 12th International Symposium on Microsomes and Drug Oxidations, 26 31 July, 1998, Montpellier, France 9. Vodicka P. Soucek P. Somorovská M. Tates AD. Zamecniková M. Vodickova L. Dusinská M. Hemminki K: Styrene genotoxicity in reinforced plastic workers: Prospects to individual risk asssessment. Pharm Toxicol 85: 53, Suppl 1, 1999, 29th EEMS, 4 9 July, 1999, Copenhagen, Denmark 10. Souček P: Expression of cytochrome P450 2A6 in Escherichia coli, spectral, and catalytic characterization, and preparation of antibodies. Proceedings of 11th International Conference on Cytochrome P450, 29 August 2 September, 1999, Sendai, Japan 11. Souček P and Gut I: Effect of microsomal system on quinone redox cycling, oxygen activation & lipoperoxidation. Proceedings of 6th Biological Reactive Intermediates Conference, 16 20 July, 2000, Paris, France 12. Souček P, Šarmanová J, Týnková L, Šůsová S, and Gut I: Genetic polymorphisms of biotransformation enzymes in population of czech republic and their use in epidemiological and mutagenesis studies. 30th EEMS, 22 26 August, 2000, Budapest, Hungary 13. Souček P: Expression of cytochrome P450 2A6 in Escherichia coli. Toxicol Lett Suppl 1/116: 24, 2000, 35th EUROTOX Meeting, 17 20 September, 2000, London, UK 14. Sarmanova J, Benesova K, Gut I, and Soucek P: Genetic polymorphisms of biotransformation enzymes in patients with non-hodgkin s lymphomas. Eur J Biochem 142-143, 2001, 27th FEBS Meeting, 30 June 5 July, 2001, Lisbon, Portugal 15. Soucek P. Anzenbacher P. Zuber R. Anzenbacherova E. Guengerich FP: Cloning expression and characterization of cytochrome P450 3A in minipig. Toxicology 164 (1-3): 146-146 Suppl. S, 2001, 9th Congress of International Union of Toxicology, 8 12 July, 2001, Brisbane, Australia 16. Sarmanova J. Susova S. Gut I. Adamek J. Kubackova K. Soucek P: Genetic polymorphisms of biotransformation enzymes and susceptibility to breast cancer. Eur J Hum Genet 10: 95-96 Suppl. 1, 2002, ESHG Meeting, 25-28 May 2002, Starsbourg, France 10
17. Soucek P. Sarmanova J. Susova S. Apltauerova M. Kubackova K. and Gut I: Genetic polymorphisms of biotransformation enzymes and susceptibility to cancer. Int J Cancer Suppl 13: 175-175, 2002, 18th UICC International Cancer Congress, 30 June 5 July, 2002, Oslo, Norway 18. Vodicka P. Kumar R. Soucek P. Vodickova L. Kuricova M. Hemminki K: An effect of genetic polymorphisms on biomarkers in styrene exposed workers. Drug Metab Rev 35: 256 Suppl. 1, 2003, 8th European ISSX Meeting, 27 April 1 May, 2003, Dijon, France 19. Anzenbacherova E. Anzenbacher P. Zuber R. Soucek P: Similarity of (Mini)pig and human liver microsomal P450 enzymes: CYP2E1. Drug Metab Rev 35: 75 Suppl. 1 2003, 8th European ISSX Meeting, 27 April 1 May, 2003, Dijon, France 20. Sarmanova J. Susova S. Gut I. Mrhalova M. Kodet R. Praausova J. Adamek J.. Soucek P: Polymorphisms in biotransformation enzymes and breast cancer. Eur J Hum Genet 11: 63-64 Suppl. 1, 2003, ESHG Meeting, 3-6 May 2003, Birmingham, England 21. Kondrová E and Souček P: The use of bacterial membranes in the study of interactions of human cytochromes P450 and xenobiotics. Chemické Listy, Symposia 97: S163, 2003, 13th International Conference on Cytochrome P450, 30 June 3 July, 2003, Prague, Czech Republic 22. Kondrová E and Souček P: The use of minipig liver microsomes in the study of interactions between cytochromes P450 and metabolites of benzene. Toxicol Lett 144 Suppl 1: S151, 2003, 41th EUROTOX Meeting, 28 September 1 October, 2003, Florence, Italy 23. Kondrová E, Stopka P. Souček P: The use of minipig liver microsomes as a model sysmtem in the study of oxidative stress induced by xenobiotics. Proceedings of 15th International Symposium on Microsomes and Drug Oxidations, 4 9 July, 2004, Mainz, Germany 24. Vaclavikova R. Stribrna J. Gut I. Soucek P: Quantification of mrna expression of cytochromes P450 in human breast tumors and healthy tissue. Proceedings of 2nd ESF Functional Genomics Conference, 6 10 September 2005, Oslo, Norway 25. Susova S. Novotny J. Vodicka P. and Soucek P.: Role of Polymorphisms of Biotransformation Enzymes in Colorectal Cancer. Drug Metab Rev 37: 346 347, Suppl. 2, 2005, 13th North American ISSX/20th JSSX Meeting, 23-27 October 2005, Maui, HI, USA 26. Stiborova M. Dracinska H. Hajkova J. Kaderabkova P. Frei E. Schmeiser HH. Soucek P. Phillips DH. Arlt VM: The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3- aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and-1a2 and NAD(P)H : quinone oxidoreductase. Mutagenesis 21 (4): 287-287, 2006, 29th Annual Meeting of the United Kingdom Environmental Mutagen Society, 19 22 March 2006,Warwick, UK 27. Soucek P, Hubackova M, Vaclavikova R, Kodet R, Mrhalova M, Gut I: Expression of cytochromes P450 in human carcinomas of the mammary gland and breast tissue without presence of carcinoma. Proceedings of EMBO Conference: Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression, 6-8 June 2006, Dublin, Ireland 28. Hlavata I. Hubackova M. Susova S. Novotny J. Vodicka P. Soucek P. Bortlik M. Kunovska M: The association of polymorphisms in biotransformation enzymes with colorectal cancer. FEBS J 273: 260-260, PP678 Suppl. 1, 2006, 31st FEBS Meeting, 24-29 June 2006, Istanbul, Turkey 29. Hlavata I. Vodickova L. Susova S. Novotny J. Vodicka P. Soucek P: Genetic polymorphisms in xenobioticmetabolizing enzymes and their association with colorectal cancer. Eur J Cancer Suppl 4 (12): 123-123, 2006, 19th EACR Meeting, 1 4 July 2006, Budapest, Hungary 30. Vodička P, Hánová M, Tulupová E, Poláková V, Naccarati A, Pardini B, Vodičková L, Souček P, Novotný J, Hemminki K. Molecular epidemiology as a tool for understanding sporadic colorectal cancer. Proceedings of 36th EEMS Meeting, 2 6 July 2006, Prague, Czech Republic 11
31. Naccarati A, Vodičková L, Kuricová M, Štětina R, Pavel Souček, Manini P, DePalma G, Marczynski B, Pardini B, Hánová M, Vodička P: Genotoxic effects and secondary oxidative stress in workers occupationally exposed to styrene. Proceedings of 36th EEMS Meeting, 2 6 July 2006, Prague, Czech Republic 32. Aimová D, Stiborova M, Soucek P, Frei E: Induction of CYP1A1 mrna and protein expression by the anticancer drug ellipticine. Proceedings of 36th EEMS Meeting, 2 6 July 2006, Prague, Czech Republic 33. Kondrová E, Stopka P. Souček P. Gut I: The influence of several phenolic antioxidants on the toxic effects of doxorubicin. Proceedings of 16th International Symposium on Microsomes and Drug Oxidations, 3 7 September, 2006, Budapest, Hungary 34. Gillam EMJ. Johnston WA. DeVoss JJ. Soucek P. Hunter DJB: DNA family shuffling of mammalian P450s from CYP2A and CYP3A subfamilies. Drug Metab Rev 38: 64-65 Suppl. 2, 2006, 14th North American ISSX Meeting, 22 26 October, 2006, Rio Grande, PR, USA 35. Hlavata I. Vodickova L. Susova S. Novotny J. Vodicka P. Soucek P: Genetic polymorphisms in xenobioticmetabolizing enzymes and their association with colorectal cancer. Eur J Cancer Suppl 4 (12): 123-123, 2006, 18th EORTC-NCI-AACR Meeting, 7 10 November 2006, Prague, Czech Republic 36. Hubackova M, Vaclavikova R, Kodet R. Mrhalova M. Gut I. and Soucek P: Role of quinone oxidoreductase (NQO1, NQO2) genes in prediction and therapy of breast cancer. Proceedings of AACR Meeting, 14 18 April 2007, Los Angeles, CA, USA 37. Hlavata I, Susova S, Pardini B, Novotny J, Vodicka P and Soucek P: Polymorphisms in glutathione S- transferase P1 increases risk of colorectal cancer. Proceedings of ESF-UB Conference in Biomedicine, 15 20 June 2007, Sant Feliu de Guixols, Spain 38. Soucek P, Hubackova M, Kodet R, Mrhalova M, Kubala E, Novotný J, Vrana D and Gut I: Role of P450 1B1 polymorphisms and expression in breast cancer. Proceedings of 15th International Conference on Cytochrome P450, 17-21 June 2007, Bled, Slovenia 39. Kondrová E, Stopka P, Souček P. Gut I: ESR spectrometry of free radicals produced by the inter-action of doxorubicin with cytochrome P450 reductase and other microsomal enzymes. Proceedings of 15th International Conference on Cytochrome P450, 17-21 June 2007, Bled, Slovenia 40. Vaclavikova R. Alnaes G. Hubackova M. Kubala E. Kodet R. Mrhalova M. Novotny J. Gut I. Kristensen VN. Soucek P: The role of multidrug resistance gene 1 (MDR1) in breast carcinoma resistance. FEBS J 274: 119-119 Suppl. 1, 2007, 32nd FEBS Meeting, 7-12 July, 2007, Vienna, Austria 41. Hlavata I. Susova S. Pardini B. Novotny J. Vodicka P. Soucek P: Significance of polymorphisms in biotransformation enzymes for colorectal carcinogenesis. Eur J Cancer Suppl 5 (4): 244-245, 2007, 14th European Cancer Conference (ECCO 14), 23-27 September, 2007, Barcelona, Spain 42. Vaclavikova R. Nordgard SH. Alnaes GA. Hubackova M. Kubala E. Kodet R. Mrhalova M. Novotny J. Gut I. Kristensen VN. Soucek P: The effect of multiple SNPs in ABCB1 gene on its expression and clinicopathological characteristics in breast cancer patients. Proceedings of 6th Annual AACR Conference: Frontiers in Cancer Prevention Research, 5 8 December 2007, Philadelphia, PA, USA 43. Hubackova M, Vaclavikova R, Kodet R. Mrhalova M. Kubala E. Gut I. and Soucek P: Evaluation of importance of polymorphisms in quinone oxidoreductases and superoxide dismutases for prediction of breast cancer risk and progression. Proceedings of 6th Annual AACR Conference: Frontiers in Cancer Prevention Research, 5 8 December 2007, Philadelphia, PA, USA 44. Hlavata I, Susova S, Vrana D, Vodickova L, Novotny J, Vodicka P and Soucek P: Polymorphisms in glutathione S-transferases increase colorectal cancer risk. Eur J Cancer Suppl 6 (9): 99-99, 2008, 20th EACR Meeting, 2 9 July 2008, Lyon, France 45. Hubackova M, Vaclavikova R, Kodet R. Mrhalova M. Kubackova K. Gut I. and Soucek P: Protein levels of NAD(P)H:quinone oxidoreductase 1 and p53 correlate in breast tumors. Cancer Res 69 (2): 297S-297S 12
Suppl., 2009, 31st Annual San Antonio Breast Cancer Symposium, 10 14 December 2008, San Antonio, TX, USA 46. Vaclavikova R. Nordgard SH. Alnaes GA. Hubackova A. Hlavata I. Kodet R. Mrhalova M. Pecha V. Kristensen VN. Gut I. Soucek P: The role of ABCB1 transporter gene in breast cancer resistance. Cancer Res 69 (2): 297S-297S Suppl., 2009, 31st Annual San Antonio Breast Cancer Symposium, 10 14 December 2008, San Antonio, TX, USA 47. Havranek O. Kleibl Z. Soucek P. Trneny M: Alterations of CHEK2 gene in non-hodgkin lymphoma patients. Haematologica 94: 273-274, Suppl. 2, 2009, 14th Annual Meeting of the European- Hematology-Association, 4-7 June 2009, Berlin, Germany 48. Hlavac V, Vaclavikova R, Ehrlichova M, Vrana D, Hlavata I, Pecha V, Trnkova M, Gut I and Soucek P. Role of ABC Transporters in Prognosis and Prediction of Outcome of Breast Carcinoma. 4 th FEBS Special Meeting: ATP Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases, 3 9 March 2012, Insbruck, Austria. 49. R. Vaclavikova, V. Hlavac, M. Ehrlichova, K. Perglerova, V. Pecha, M. Trnkova, M. Mrhalova, R. Kodet, L. Rob, I. Gut and P. Soucek. Expression profile and genetic variability of ABCB1 and ABCC1 genes and their role in prognosis of breast and ovarian carcinoma. 4 th FEBS Special Meeting: ATP Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases, 3 9 March 2012, Insbruck, Austria. 50. Ehrlichova M, Vaclavikova R, Brynychova V, Nemcova V, Pecha V, Mrhalova M, Rob R, Ojima I, Gut I and Soucek P. Efficiency and transport of taxanes in human cancer cell lines and solid tumors. 22 nd Biennial Congress of the European Association for Cancer Research (EACR), 7 10 July 2012, Barcelona, Spain. Abstract published in Eur J Cancer 2012;48(Suppl 5):S252. 51. B. Mohelnikova-Duchonova, V. Brynychova, M. Oliverius, Z. Kala, E. Honsova, K. Muckova, I. Penka, V. Prochazka, J. Hlavsa, P. Souček, Differences In Gene Expression Of ABC Transporters In Pancreatic Adenocarcinoma, 44th Meeting of European Pancreatic Club, 20 23 June 2012, Prague, Czech Republic. Abstract published in Pancreatology 2012;12:507. 52. P. Souček, B. Mohelniková-Duchonová, V. Brynychová, M. Oliverius, E. Honsová, Association of KRAS pathway with expression of ABC transporters in pancreatic adenocarcinoma, 44th Meeting of European Pancreatic Club, Prague, 20 23 June 2012, Czech Republic. Abstract published in Pancreatology 2012;12:514-5. b/ přednášky 1. Pavel Souček: Genetic polymorphisms of biotransformation enzymes in patients with lymphomas, 29th MEDICHEM Congress, 4 6 September 2001, Prague, Czech Republic 2. Pavel Souček: Breast cancer: role of polymorphisms in biotransformation enzymes, 3rd International Workshop on Mammary Gland Biotechnology: Nutrition, Genomics and Breast Cancer, 29 September 1 October 2005, Barcelona Spain 3. Pavel Souček: Biotransformation enzymes as modifiers in breast cancer, 36th Annual Meeting of the European Environmental Mutagen Society "From Genes to Molecular Epidemiology" 2 6 July 2006, Prague, Czech Republic 4. Pavel Souček: The use of minipig as a model species for the testing of metabolism and toxicity of anticancer drugs in vitro, Pig Genome II Meeting, 4 5 June 2008, Ljubljana, Slovenia 5. Souček P, Václavíková R, Ehrlichová M, Kovář J, Šimek P, Ojima I and Gut I. Effects of classical and experimental taxanes in cell line models. International Congress on Natural Anticancer Drugs, 30 June 4 July 2012, Olomouc, Czech Republic. Abstract published in Biomedical Papers 2012;156(Suppl 1):S30. 10) Přednášky a postery na národních konferencích, sympoziích a odborných setkáních 13
a/ postery 1. Souček P, Hubáčková M, Kodet R, Mrhalová M, Kubala E, Novotný J, Vrána D and Gut I: Role of P450 1B1 polymorphisms and expression in breast cancer. Celostátní sjezd Společnosti lékařské genetiky SLG ČLS JEP, 19 21 září 2007, Praha 2. Hubáčková M, Václavíková R, Kodet R, Mrhalová M, Gut I a Souček P: Úloha exprese cytochromů P450 v rozvoji a terapii karcinomu prsu. XXXII. Brněnské onkologické dny, 17 19. duben, 2008, Brno 3. Vaclavikova R, Nordgard SH, Alnaes GA, Hlavata I, Kodet R, Mrhalova M, Pecha V, Kozevnikovova R, Julisova I, Pohnetalova D, Trnkova M, Kristensen VN, Gut I and Souček P: The role of ABC transporter genes in breast cancer resistance. XXXIII. Brněnské onkologické dny, 16 18. duben, 2009, Brno b/ přednášky 1. Souček P: Studium úlohy cytochromů P450 v karcinogenezi. Chemické listy 94: 512, 2000, XVII. biochemický sjezd, 7 10, září 2000, Praha 2. Souček P, Šarmanová J a Gut I: Genetické polymorfismy biotransformačních enzymů v české populaci. 23. pracovní dny České a Slovenské společnosti pro mutagenezu zevním prostředím při Československé biologické společnosti, 9 11. květen 2000, Brno 3. Souček P a Gut I: Studium účinků chinonů na oxidativní stres a cytochromy P450 v lidských mikrosomech. XXI. Xenobiochemické symposium, 30. květen 1. červen 2001, Valtice 4. Souček P, Šarmanová J, Šůsová S and Gut I: Breast cancer: role of polymorphisms in biotransformation enzymes. 26. pracovní dny České a Slovenské společnosti pro mutagenezu zevním prostředím při Československé biologické společnosti, 5 7. květen 2003, Brno 5. Šarmanová J. Šůsová S. Gut I. Mrhalová M. Kodet R. Prauzová J. Roth Z. Souček P: Genetický polymorfismus a vnímavost k rakovině prsu. VIII. Onkogenetický den, 11. červen 2003, Praha 6. Souček P, Šarmanová J, Šůsová S, Mrhalová M, Kodet R, Adámek J, Roth Z, and Gut I: Breast cancer: role of polymorphisms in biotransformation enzymes, XXII. Xenobiochemické symposium, 9 11. červen 2003, Smolenice 7. Souček P, Trněný M, Šůsová S a Šarmanová J: Biotransformační enzymy a non-hodgkin lymfomy: genotypy versus exprese mrna. 27. pracovní dny České a Slovenské společnosti pro mutagenezu zevním prostředím při Československé biologické společnosti, 5 7. květen, 2004, Brno 8. Souček P: Genetické polymorfismy a nádory, Specializační kurz č. 207202 Nádory a povolání, 25 26. duben 2005, IPVZ, Praha 9. Souček P, Šůsová S, Vodička P a Novotný J: Genetické polymorfismy a jejich úloha v karcinogenezi. XXIII. Xenobiochemické symposium, 16 19. květen 2005, Valtice 10. Souček P, Šůsová S, Vodička P a Novotný J: Úloha genetických polymorfismů biotransformačních enzymů v karcinogenezi, 10. Česko-slovenská mezioborová toxikologická konference TOXCON, 2005, 14 16. září, Olomouc 11. Souček P, Václavíková R, Hubáčková M, Kodet R, Mrhalová M a Gut I: Exprese cytochromů P450 u pacientek s rakovinou prsu, 29. pracovní dny České a Slovenské společnosti pro mutagenezu zevním prostředím při Československé biologické společnosti, 2 4. květen 2006, Brno 12. Souček P, Hubáčková M, Václavíková R, Kodet R, Mrhalová M, Jan Novotný a Gut I: Úloha exprese cytochromů P450 v rozvoji a terapii karcinomu prsu. 30. pracovní dny České a Slovenské společnosti pro mutagenezu zevním prostředím při Československé biologické společnosti, 5 7. květen 2007, Brno 14